Senzime AB (publ) (SEZI.ST)
SEK 5.64
(-1.05%)
SEK 5.64
(-1.05%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 433.54 Million SEK | 34.36% |
| 2022 | 322.68 Million SEK | 84.79% |
| 2021 | 174.62 Million SEK | -32.55% |
| 2020 | 258.89 Million SEK | 37.88% |
| 2019 | 187.76 Million SEK | -4.77% |
| 2018 | 197.15 Million SEK | 18.75% |
| 2017 | 166.03 Million SEK | 6.22% |
| 2016 | 156.31 Million SEK | 226.99% |
| 2015 | 47.8 Million SEK | 3.21% |
| 2014 | 46.31 Million SEK | 19.9% |
| 2013 | 38.63 Million SEK | 16.24% |
| 2012 | 33.23 Million SEK | 4.97% |
| 2011 | 31.65 Million SEK | 22.12% |
| 2010 | 25.92 Million SEK | 22.41% |
| 2009 | 21.17 Million SEK | -8.56% |
| 2008 | 23.16 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 409.84 Million SEK | -5.46% |
| 2024 Q2 | 393.2 Million SEK | -4.06% |
| 2023 FY | 433.54 Million SEK | 34.36% |
| 2023 Q4 | 433.54 Million SEK | 18.39% |
| 2023 Q1 | 366.91 Million SEK | 13.71% |
| 2023 Q2 | 342.63 Million SEK | -6.62% |
| 2023 Q3 | 366.18 Million SEK | 6.87% |
| 2022 Q3 | 575.42 Million SEK | 156.01% |
| 2022 Q4 | 322.68 Million SEK | -43.92% |
| 2022 Q1 | 154.09 Million SEK | -11.76% |
| 2022 FY | 322.68 Million SEK | 84.79% |
| 2022 Q2 | 224.76 Million SEK | 45.87% |
| 2021 FY | 174.62 Million SEK | -32.55% |
| 2021 Q2 | 216.2 Million SEK | -8.91% |
| 2021 Q1 | 237.35 Million SEK | -8.32% |
| 2021 Q3 | 195.6 Million SEK | -9.53% |
| 2021 Q4 | 174.62 Million SEK | -10.72% |
| 2020 Q2 | 233.23 Million SEK | 31.47% |
| 2020 Q1 | 177.4 Million SEK | -5.52% |
| 2020 FY | 258.89 Million SEK | 37.88% |
| 2020 Q4 | 258.89 Million SEK | 51.64% |
| 2020 Q3 | 170.72 Million SEK | -26.8% |
| 2019 Q4 | 187.76 Million SEK | -4.34% |
| 2019 FY | 187.76 Million SEK | -4.77% |
| 2019 Q2 | 174.74 Million SEK | -5.46% |
| 2019 Q1 | 184.84 Million SEK | -6.24% |
| 2019 Q3 | 196.28 Million SEK | 12.33% |
| 2018 Q3 | 176.68 Million SEK | -3.51% |
| 2018 Q2 | 183.11 Million SEK | -2.53% |
| 2018 FY | 197.15 Million SEK | 18.75% |
| 2018 Q4 | 197.15 Million SEK | 11.59% |
| 2018 Q1 | 187.86 Million SEK | 13.15% |
| 2017 Q1 | 173.24 Million SEK | 10.83% |
| 2017 Q2 | 170.02 Million SEK | -1.86% |
| 2017 Q3 | 168.23 Million SEK | -1.06% |
| 2017 Q4 | 166.03 Million SEK | -1.31% |
| 2017 FY | 166.03 Million SEK | 6.22% |
| 2016 Q4 | 156.31 Million SEK | -2.26% |
| 2016 Q3 | 159.91 Million SEK | -2.77% |
| 2016 FY | 156.31 Million SEK | 226.99% |
| 2016 Q2 | 164.47 Million SEK | 256.31% |
| 2016 Q1 | 46.16 Million SEK | -3.43% |
| 2015 FY | 47.8 Million SEK | 3.21% |
| 2015 Q3 | 49.82 Million SEK | -3.66% |
| 2015 Q4 | 47.8 Million SEK | -4.06% |
| 2015 Q1 | 42.27 Million SEK | -8.73% |
| 2015 Q2 | 51.71 Million SEK | 22.34% |
| 2014 FY | 46.31 Million SEK | 19.9% |
| 2014 Q4 | 46.31 Million SEK | 39.59% |
| 2014 Q3 | 33.18 Million SEK | -3.29% |
| 2014 Q2 | 34.3 Million SEK | 0.0% |
| 2014 Q1 | - SEK | -100.0% |
| 2013 Q4 | 38.63 Million SEK | 0.0% |
| 2013 Q2 | 30.24 Million SEK | 0.0% |
| 2013 Q1 | 30.24 Million SEK | -8.97% |
| 2013 FY | 38.63 Million SEK | 16.24% |
| 2012 Q4 | 33.23 Million SEK | 0.0% |
| 2012 FY | 33.23 Million SEK | 4.97% |
| 2012 Q2 | 28.98 Million SEK | 0.0% |
| 2011 FY | 31.65 Million SEK | 22.12% |
| 2011 Q4 | 31.65 Million SEK | 0.0% |
| 2011 Q2 | 32.52 Million SEK | 0.0% |
| 2010 Q4 | 25.92 Million SEK | 0.0% |
| 2010 Q2 | 26.93 Million SEK | 0.0% |
| 2010 FY | 25.92 Million SEK | 22.41% |
| 2009 Q4 | 21.17 Million SEK | 0.0% |
| 2009 FY | 21.17 Million SEK | -8.56% |
| 2008 FY | 23.16 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | -589.431% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 86.812% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 86.812% |
| Arcoma AB | 81.96 Million SEK | -428.955% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | 36.513% |
| BICO Group AB (publ) | 10.19 Billion SEK | 95.748% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | 42.585% |
| CellaVision AB (publ) | 928.71 Million SEK | 53.318% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | -651.047% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -1874.642% |
| C-Rad AB (publ) | 404 Million SEK | -7.312% |
| Duearity AB (publ) | 15.14 Million SEK | -2762.797% |
| Dignitana AB (publ) | 44.83 Million SEK | -867.059% |
| Episurf Medical AB (publ) | 104.3 Million SEK | -315.668% |
| Getinge AB (publ) | 55.09 Billion SEK | 99.213% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | -322.398% |
| Iconovo AB (publ) | 128.07 Million SEK | -238.493% |
| Integrum AB (publ) | 164.85 Million SEK | -162.977% |
| Luxbright AB (publ) | 40.68 Million SEK | -965.563% |
| Mentice AB (publ) | 322.52 Million SEK | -34.421% |
| OssDsign AB (publ) | 356.38 Million SEK | -21.649% |
| Paxman AB (publ) | 167.12 Million SEK | -159.412% |
| Promimic AB (publ) | 92.87 Million SEK | -366.802% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -1010.337% |
| SciBase Holding AB (publ) | 64.33 Million SEK | -573.892% |
| ScandiDos AB (publ) | 81.47 Million SEK | -432.13% |
| Sectra AB (publ) | 3.21 Billion SEK | 86.498% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 57.247% |
| SpectraCure AB (publ) | 144.83 Million SEK | -199.337% |
| Stille AB | 804.89 Million SEK | 46.137% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 97.355% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 80.254% |